Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease (Prodygi-II)
Prospective Study of Dysarthria, and the Appearance of Non-dopaminergic Signs in Idiopathic PARKinson's Disease
Pilot study:
- Longitudinal follow up of the PRODY-GI cohort for parkinson's disease (PD)
- Observational study of upper and lower axial symptoms' occurence in 30 PD patients in on and off drug conditions, 30 aged matched control subjects and 10 control subjects with supra nuclear palsy
- Multi modal approach: functional MRI, clinical , ENT assessment, respiratory assessment, neuropsychological and gait evaluations
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Prospective, clinical assessment of :
- Cognition and diadochokinetic task during fMRI in 30 PD patients (in off and on condition)
- Motor assessment using VICON gait and balance analysis
- Pulmonary functional testing in OFF and ON drug condition
- Quality of life
- Clinical neurological MDS UPDRS , N Fog questionnaire
- ENT and speech therapist evaluation in OFF and ON drug condition
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Caroline MOREAU, MD
- Phone Number: +33 3.20.44.67.52
- Email: caroline.moreau@chru-lille.fr
Study Locations
-
-
-
Lille, France
- Hôpital Roger Salengro, CHRU
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Parkinson's Disease group :
Patients with Parkinson's Disease, who where included in the PRODYGI-1 cohort still meeting the MP criteria, Always followed in the service of neurology and pathology of the movement.
Pathological control group:
- Patients suffering from Richardson syndrome.
- Aged over 18
Healthy control group:
- Age-matched (± 5 years)
- Recruited on the basis of volunteering.
- free from any progressive neurological pathology after clinical examination and MoCA.
Exclusion Criteria:
For all groups:
- Pregnant or lactating woman
- Extra-neurological severe respiratory pathology
- Terminal heart failure
- Contraindication to MRI
- Refusal / withdrawal / inability to give consent
- ENT pathology.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
PD patients
30 PD patients in ON and OFF levodopa conditions
|
|
Healthy control subjects
30 age matched healthy control subjects
|
|
Neurological control subjects
10 patients with defined supra nuclear palsy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the neural network between patients in OFF levodopa conditions and control subjects
Time Frame: Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Measure evaluated by functional MRI during the realisation of a cognitive task: symbol digit modality test
|
Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the neural network between patients in OFF-drug conditions and healthy control subjects
Time Frame: Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Measure evaluated by functional MRI during the realisation of two motor tasks
|
Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
|
Change in the neural network between patients in OFF-drug conditions and healthy control subjects
Time Frame: Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Measure evaluated by resting state functional MRI
|
Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
|
Change in the neural network between OFF-drug condition and ON-drug condition in patients
Time Frame: Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Measure evaluated by functional MRI, during the realisation of one cognitive task and two motor tasks
|
Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
|
Change in the neural network between patients in OFF-drug conditions and neurological control subjects (with supra nuclear palsy)
Time Frame: Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Measure evaluated by functional MRI, during the realisation of one cognitive task and two motor tasks
|
Between two evaluation visits, on average at 3 months (baseline- 3 months)
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Caroline MOREAU, MD, University Hospital, Lille
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimated)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2015_89
- 2016-A01544-47 (Other Identifier: ID-RCB number, ANSM)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.